Diamedica Therapeutics (DMAC) Stock News

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced participation in one-on-one meetings at the upcoming BTIG Biotechnology Conference on August 8-9, 2022, held at the St. Regis New York Hotel and virtually. The company focuses on developing treatments for neurological and kidney diseases, with its lead candidate DM199 being a recombinant form of the human tissue kallikrein-1 protein. Interested attendees can schedule meetings through their BTIG representatives. For further information, visit www.diamedica.com.

DiaMedica Therapeutics (NASDAQ: DMAC) has announced a clinical hold on its Phase 2/3 ReMEDy2 trial for DM199, aimed at treating acute ischemic stroke (AIS) patients. This hold follows the submission of serious adverse event reports related to transient hypotension in three patients after initial dosing. The company attributes these incidents to a change in IV bag materials used compared to prior trials and is working with the FDA to modify the trial protocol. Despite the setback, DiaMedica remains confident in DM199's potential for improving stroke outcomes.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced its participation in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022. The company, focused on developing treatments for neurological disorders and kidney diseases, will hold one-on-one meetings with investors during the virtual event. DiaMedica's lead candidate, DM199, is a recombinant form of the human tissue kallikrein-1 protein, aimed at treating acute ischemic stroke and chronic kidney disease. For more information, visit www.diamedica.com.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has announced an expansion of its clinical study sites for the Phase 2/3 ReMEDy2 trial on DM199, treating acute ischemic stroke. The company currently has 9 active sites, more than double that of March 2022. However, site activation and patient enrollment have been slower than expected due to COVID-19-related staffing issues. Financially, DiaMedica reported a decrease in total cash and investments to $41.0 million as of March 31, 2022, down from $45.1 million in December 2021. Conference call scheduled for May 5, 2022.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its Q1 2022 financial results after market close on May 4, 2022. A live conference call is scheduled for May 5, 2022, at 7:00 AM CT to discuss the results and provide a business update. The company is focused on developing novel treatments for neurological disorders and kidney diseases, with its lead candidate DM199 targeting acute ischemic stroke and chronic kidney disease. This call offers investors crucial insights into the company’s financial health and strategic direction.

DiaMedica Therapeutics (Nasdaq: DMAC) provided a business update and financial results for the year ending December 31, 2021, highlighting a strong balance sheet with $45M in cash, offering a runway into 2024. The company is currently dosing patients in the pivotal Phase 2/3 ReMEDy2 trial for acute ischemic stroke, which aims to enroll 350 patients. New executive appointments were announced, enhancing the leadership team. R&D expenses slightly increased to $8.8M, while general and administrative expenses grew to $4.9M. A conference call is scheduled for March 15, 2022, to discuss these results.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its fourth quarter 2021 financial results after market close on March 14, 2022. A live conference call to discuss these results and provide a business update will take place on March 15, 2022, at 7:00 AM CT. Interested parties can participate via dial-in or webcast. DiaMedica is focused on novel treatments for neurological disorders and kidney diseases, with its lead candidate DM199 targeting acute ischemic stroke and chronic kidney disease.

DiaMedica Therapeutics (NASDAQ: DMAC) announced the appointment of Dominic Cundari as Chief Commercial Officer, focusing on the commercial launch of DM199 for acute ischemic stroke. With over 20 years in specialty biopharmaceuticals, Cundari previously held senior roles at Genentech, enhancing their vascular franchise. The company granted him inducement stock options for 165,000 shares at $2.90 each. DM199, a synthetic form of KLK1, is under FDA's Fast Track Designation for the treatment of acute ischemic stroke, aiming to improve outcomes for untreated patients.

DiaMedica Therapeutics (NASDAQ: DMAC) will present two abstracts at the American Heart Association 2022 International Stroke Conference in New Orleans from February 9-11, 2022. The abstracts focus on:

• Stroke Recurrence and Mortality with Recombinant Tissue Kallikrein Protein in the Remedy1 Phase 2 Trial
• Randomized, Double-blind, Placebo-controlled Study to Evaluate DM199 for Acute Ischemic Stroke (ReMEDy2 Trial)

Presentations will occur on February 10, 2022, from 12:30 PM to 1:15 PM at Poster Hall B2. Visit DiaMedica's website for more details.